ArticleLiver cancer2018
The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade.
Article in Liver cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.World journal of gastroenterology · 2020Pooled it
- CATS-BIT-ME Score: A Machine Learning and Conventional Risk Model for Prognosis in Hepatocellular Carcinoma.Gastro hep advances · 2026Article
- Tumor size larger than 6.5 cm and microvascular invasion are comparable prognosticators for hepatocellular carcinoma: a multi-institutional observational study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Preoperative integrated oxidative stress score as a prognostic factor for predicting clinical outcomes in breast cancer patients received neoadjuvant chemotherapy: a real-world retrospective study.International journal of medical sciences · 2025Article
- Article
- Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma.Clinical and molecular hepatology · 2024Article
- Interactive model for predicting the oncological outcome of patients with early-stage huge hepatocellular carcinoma after hepatectomy: a multicenter population-based study.Updates in surgery · 2024Article
- Nomogram for predicting overall survival in patients with large (>5 cm) hepatocellular carcinoma based on real-world practice.Journal of liver cancer · 2023Article
- Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysis.The Kaohsiung journal of medical sciences · 2023Article
- Prognostic Analysis of Single Large Hepatocellular Carcinoma Following Radical Resection: A Single-Center Study.Journal of hepatocellular carcinoma · 2023Article
- A proposal for T1 subclassification in hepatocellular carcinoma: reappraisal of the AJCC 8th edition.Hepatology international · 2022Article
- Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture.Scientific reports · 2022Article
- Differential prognoses among male and female patients with hepatocellular carcinoma.Journal of the Chinese Medical Association : JCMA · 2022Article
- A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma.Cancers · 2022Article
- The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients.Journal of immunology research · 2022Article
- Chemoembolization for Single Large Hepatocellular Carcinoma with Preserved Liver Function: Analysis of Factors Predicting Clinical Outcomes in a 302 Patient Cohort.Life (Basel, Switzerland) · 2021Article
- Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma.Hepatology international · 2021Article
- Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs.Cancers · 2021Article
- The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma.Journal of the Chinese Medical Association : JCMA · 2021Article
- m6A Modification-MediatedFrontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsWhether single large hepatocellular carcinoma (SLHCC) is classified as Barcelona Clinic Liver Cancer (BCLC) stage A or B is still controversial. We aimed to compare the clinical manifestations, treatment modalities, and prognoses among patients with SLHCC and those in BCLC stage A and B.
methodsWe enrolled 2,285 treatment-naive hepatocellular carcinoma (HCC) patients with BCLC stage A or B from October 2007 to December 2015. Factors in terms of prognoses were analyzed by multivariate analysis.
resultsWe enrolled 1,210, 466, and 609 patients in a BCLC-A, SLHCC, and BCLC-B group, respectively. After a median follow-up duration of 21.2 months, 898 patients had died. The cumulative 5-year survival rates were 57.0, 42.6, and 27.3% for patients in the BCLC-A, SLHCC, and BCLC-B groups, respectively, which were significantly different (
conclusionPatients in the SLHCC group had an overall survival rate intermediate to those of the BCLC-A and BCLC-B groups. It is suggested that the SLHCC group could be classified as occupying a different stage from the BCLC stages A and B. The ALBI grade could help to stratify SLHCC into a different prognostic group. However, the results need to be validated externally in other regions of the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.